Key result
Among STEMI patients surviving to discharge after multivessel PCI, 10.3% were readmitted within 30 days, with female sex, CKD, CHF, anemia, and MCS use as significant predictors.
Why the study?
Although trials show benefits from nonculprit vessel PCI in select STEMI patients with multivessel CAD, 30-day readmission rates and causes in this high-risk population remain unknown.
What are the rates, causes, and predictors of 30-day readmission in STEMI patients undergoing multivessel PCI?
Cohort (n=22,257)
Yes
What are the rates, causes, and predictors of 30-day readmission in STEMI patients undergoing multivessel PCI?
Approximately 10% of STEMI patients undergoing multivessel PCI are readmitted within 30 days, predominantly for cardiac causes, highlighting a high-risk population requiring close post-discharge follow-up.
Highlights 10% 30-day readmission burden after multivessel PCI in STEMI; leaves open targeted risk stratification for prospective trials.
No takes yet. Share an insight, caveat, or question.
Tripathi et al. (2019) conducted a cohort in ST-elevation myocardial infarction (STEMI) with multivessel coronary artery disease (n=22,257). Multivessel percutaneous coronary intervention was evaluated on 30-day readmission. Among STEMI patients surviving to discharge after multivessel PCI, 10.3% were readmitted within 30 days, with female sex, CKD, CHF, anemia, and MCS use as significant predictors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: